DiagnoCure Q1 Revenues Fall 12 Percent on Weak Sales of Hologic-marketed Prostate Cancer Assay | GenomeWeb

NEW YORK (GenomeWeb News) – Cancer diagnostics firm DiagnoCure said on Friday that revenues for the first quarter of its fiscal year 2014 decreased 12 percent year over year.

DiagnoCure's revenues are derived completely from royalties from the sale of the Progensa PCA3 assay for prostate cancer, marketed by Hologic, and the Quebec City-based company attributed the year-over-year revenue drop on Hologic's failure to promote and market the test.

Get the full story

This story is free
for registered users

Registering provides access to this and other free content.

Register now.

Already have an account?
Login Now.

Kuwait says it will alter its law requiring citizens and visitors to provide DNA samples, New Scientist reports.

In Science this week: convergent evolution in bird hemoglobin, and more.

The Wall Street Journal speaks with patients affected by questionable test results from Theranos.

Researchers link variants in TACR3 to hot flashes during menopause, Live Science reports.